Search
Search
Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD
Show Description +
How do retina specialists define disease activity and disease control in Neovascular (Wet) Age-Related Macular Degeneration (AMD)? Moderator Daniel F. Kiernan, MD, FACS, asks panelists Prethy Rao, MD, MPH, FACS, and Andrew M. Schimel, MD, how they determine when a patient's Wet AMD is responding adequately to treatment, and explores how much they value anatomic responses and functional responses.
Posted: 3/13/2025
Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD
How do retina specialists define disease activity and disease control in Neovascular (Wet) Age-Related Macular Degeneration (AMD)? Moderator Daniel F. Kiernan, MD, FACS, asks panelists Prethy Rao, MD, MPH, FACS, and Andrew M. Schimel, MD, how they determine when a patient's Wet AMD is responding adequately to treatment, and explores how much they value anatomic responses and functional responses.
Posted: 3/13/2025
Assessing Treatment Paradigms in Wet AMD and DME Therapy in the Age of Extended Dosing Intervals: Parts 1 and 2
Assessing Treatment Paradigms in Wet AMD and DME Therapy in the Age of Extended Dosing Intervals: Part 3
About Regeneron
Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.
Visit us online: regeneron.com
Follow Regeneron
EYLEA HD is a registered trademark of Regeneron Pharmaceuticals, Inc.
© 2025 Regeneron Pharmaceuticals, Inc. All rights reserved.
03/2025
US.EHD.25.02.0123
